AstraZeneca and Abbisko combine TAGRISSO with first-in-class oral PD-L1 drug for NSCLC
July 02, 2026 | 16:27
Abbisko Therapeutics (HKEX: 02256) and AstraZeneca (NYSE: AZN) entered a strategic collaboration to jointly advance Lumipodlin (ABSK043), a first-in-class oral PD-L1 inhibitor, in combination with TAGRISSO in non-small cell lung cancer clinical trials.
Latest News
Mobile Version